Company: SHPH
Filing Date: 2025-03-13
Form Type: 8-K
Source: 0001493152-25-010211
Chunk: 1

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-13
Form: 8-K
Item: Item 1.01
Chunk 1
---
 radiation sensitizer
Ropidoxuridine, and for working capital and general corporate purposes. In addition, the Company may use up to $2.0 million for marketing
and advertising services to communicate information about the Company to the financial community. The Company presently works with two
IR/PR firms and is planning to engage an additional firm to bolster the Company’s marketing and advertising outreach.

The
Company made certain customary representations, warranties and covenants concerning the Company and the registration statement in the
Underwriting Agreement and also agreed to indemnify the Underwriter against certain liabilities, including liabilities under the Securities
Act of 1933, as amended (the “ Securities Act”). The Offering was made pursuant to the Company’s registration statement
on Form S-1 (File No. 333-284889), filed with the Securities and Exchange Commission (the “ Commission”) and declared effective
on March 7, 2025, as supplemented by a final prospectus supplement dated March 12, 2025.

The
foregoing description of the terms of the Underwriting Agreement and Pre-Funded Warrants does not purport to be complete and is subject
to, and qualified in its entirety by, the full text of the Underwriting Agreement and Pre-Funded Warrants which are attached as Exhibit
1.1 and Exhibit 4.1 hereto and are incorporated by reference herein.

Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.